|Bid||1.9300 x 1100|
|Ask||1.9900 x 1000|
|Day's Range||1.9000 - 2.2000|
|52 Week Range||1.5600 - 9.2000|
|Beta (3Y Monthly)||2.01|
|PE Ratio (TTM)||N/A|
|Earnings Date||Sep 27, 2018 - Sep 27, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.50|
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Pivotal Software (NYSE: PVTL ) shares were ...
Some recent biopharma news concerning Akari Therapeutics has AKTX stock flying high on Wednesday.Source: Shutterstock The biopharma news has to do with Akari Therapeutics (NASDAQ:AKTX) getting Fast Track designation from the U.S. Food & Drug Administration (FDA) for one of its treatments. This allows the company to speed up testing of the drug. The designation is typically given to medicine with potential to treat illnesses that don't already have wide coverage.The Fast Track designation from the FDA is for Akari Therapeutics' nomacopan. This is the company's drug for treating HSCT-TMA. HSCT-TMA is an orphan condition with an estimated fatality rate of more than 80% in children that suffer from it. There currently isn't an approved treatment for this illness.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe positive biopharma news for AKTX stock comes after the successful treating of two patients in the U.S. with nomacopan. With these results and the FDA's approval, the company is now planning to launch a clinical trial of the treatment in the fourth quarter of 2019. * 15 Growth Stocks to Buy for the Long Haul "We see HSCT-TMA as a gateway into a range of other poorly treated orphan TMAs in both pediatric and adult patients, and are optimistic about the potential for nomacopan to offer an improved standard of care for these orphan conditions with high mortality rates," Clive Richardson, interim CEO of Akari Therapeutics, said in a statement.AKTX stock was up 32% as of Wednesday morning and is up 7% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Growth Stocks to Buy for the Long Haul * 5 More Cloud Stocks With Plenty of Potential * 5 Clean Energy ETFs to Buy for 2019 As of this writing, William White did not hold a position in any of the aforementioned securities.The post Biopharma News: Why Akari Therapeutics (AKTX) Stock Is Soaring Today appeared first on InvestorPlace.
Shares of Akari Therapeutics PLC rocketed 61% to pace all premarket gainers in very active trading Wednesday, after the biopharmaceutical company said its treatment (nomacopan) of stem-cell transplant associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients was granted "Fast Track" designation by the U.S. Food and Drug Administration. Trading volume swelled to 1.7 million shares, compared with the full-day average of about 96,000 shares. A Fast Track designation helps facilitate the development and expedite the review of new drugs for the treatment of serious or life-threatening conditions that address unmet medical needs. ""Fast Track designation provides our HSCT-TMA clinical program a pathway for an expedited approval for nomacopan, and we plan to commence a pivotal trial in the fourth quarter of 2019," said Chief Executive Clive Richardson. The stock has tumbled 42% over the past three months, while the iShares Nasdaq Biotechnology ETF has gained 2.9% and the S&P 500 has tacked on 3.2%.
Fast Track designation by the U.S. Food and Drug Administration (FDA) facilitates the development and expedites the review of new medicines like nomacopan that treat serious unmet medical needs and in Akari’s case, pediatric patients with HSCT-TMA. The Fast Track designation follows a successful pre-investigational new drug (IND) FDA meeting earlier this year regarding Akari’s proposed pivotal clinical trial program for HSCT-TMA. The FDA is working with Akari in its optimization of pediatric dosing for HSCT-TMA by Akari’s participation in the FDA Model-Informed Drug Development (MIDD) Program with supportive PK data provided by pediatric patients already treated with nomacopan as part of a named patient program.
Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced new preclinical and human data demonstrating the potential benefits of the dual inhibition of complement (C5) and leukotriene (LTB4) pathways by nomacopan for the treatment of pemphigoid disease (PD).
Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced an oral presentation will be given at the 28th EADV Congress. The oral presentation will describe the safety and efficacy data from Akari’s Phase II clinical trial of nomacopan in adult patients with mild to moderate bullous pemphigoid.
Anyone researching Akari Therapeutics, Plc (NASDAQ:AKTX) might want to consider the historical volatility of the share...
Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced that it has entered into definitive agreements with certain institutional investors, accredited investors and an existing shareholder, RPC Pharma Ltd., an affiliated entity of Dr. Ray Prudo, Akari’s Chairman, to receive gross proceeds of $4.5 million. In connection with the offering, the Company will issue approximately 2,368,421 registered American Depository Shares (ADSs) of Akari at a purchase price of $1.90 per ADS in a registered direct offering.
The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.
Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.
Akari announced positive results for Part A of a Phase 1/2 study dubbed TRACKER that evaluated the safety and efficacy of its topical nomacopan in moderate to severe atopic keratoconjunctivitis. The secondary objective of efficacy was assessed using a standard composite scoring system. Atopic keratoconjunctivitis is a serious corneal and eye surface disease which ultimately leads to visual impairment.
Part A of a safety and efficacy study successfully completed with nomacopan eye drops which were well tolerated with no serious adverse events. All patients were on maximal dosage of cyclosporin, the standard of care, for at least three months prior to treatment. Improvement in the composite clinical score was seen in signs and symptoms reflecting the potential for both reduced corneal damage and improved patient comfort.
Positive initial clinical data reported in ongoing bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) clinical trialsFurther clinical data from BP and AKC trials.
- Biotech and healthcare stocks are loved by traders for their big price moves, which can happen when a company makes progress (or faces problems) with their developmental products like drugs and devices. Results from Phase I, II and III clinical studies, and FDA or European approvals (and rejections), can send stocks into the headlines. Recent examples include Mustang Bio (MBIO) and Akari Therapeutics (AKTX) with their respective human study results.
In an experimental back of the eye, autoimmune uveitis (EAU) model to be reported in a poster presentation at ARVO 2019, nomacopan (Coversin) and its long acting variants.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) BIONDVAX PHARMA/S ADR (NASDAQ: BVXV ) Eidos Therapeutics ...
Treatment with Nomacopan (Coversin) in three patients with mild-to-moderate bullous pemphigoid (BP) resulted in no drug-related adverse events and rapid reduction in BP Disease.
CORAL GABLES, FL / ACCESSWIRE / April 23, 2019 / The stock market is on the verge of setting new record highs today April 23, 2019. Today we are highlighting: Akari Therapeutics, Plc (AKTX), Twitter Inc. (TWTR), Bank of America Corporation (BAC), Leafbuyer Technologies, Inc. (LBUY). Akari Therapeutics, Plc (AKTX) (Market Cap: $65.409M) traded higher on Tuesday 4/23/2019 after making a big announcement.
Akari Therapeutics PLC (NASDAQ: AKTX ) shares were surging Tuesday, breaking above the $4 barrier for the first time in about a month. What Happened The microcap biotech — which focuses on therapies for ...
Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces positive initial Phase II clinical data from the first three of bullous pemphigoid (BP) patients in an ongoing clinical trial.
Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announces that it will provide an update on its eye diseases program during the 2019 Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO) being held April 28-May 2, 2019 in Vancouver, B.C. A poster will be presented at ARVO showing Coversin’s effect in a preclinical model of autoimmune uveitis, a back of the eye orphan disease with significant unmet need.
CORAL GABLES, FL / ACCESSWIRE / March 18, 2019 / The tech stock market is truly miraculous, mainly because the tech industry never ceases to amaze consumers as companies consistently demonstrate their ability to innovate towards the future. Over the course of the last few months, we've seen tech companies design and invent in the areas of data analytics, artificial intelligence, augmented reality, and a plethora of others. ParcelPal Technology Inc (PTNYF) (PKG), Conformis Inc (CFMS), Digital Turbine Inc (APPS), and Akari Therapeutics Plc (AKTX) represent 4 tech stocks on the rise on Monday.
Every investor in Akari Therapeutics, Plc (NASDAQ:AKTX) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tendRead More...